Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PARD
Previous Symbol
CUSIPN/A
Phone206-286-2501
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares1,500,000
Market Cap$70,000.00
OptionableNot Optionable
Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions
What is Poniard Pharmaceuticals' stock symbol?
Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."
Has Poniard Pharmaceuticals been receiving favorable news coverage?
Headlines about PARD stock have trended neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Poniard Pharmaceuticals earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term.
Who are some of Poniard Pharmaceuticals' key competitors?
Some companies that are related to Poniard Pharmaceuticals include Myrexis (MYRX), Aeolus Pharmaceuticals (AOLS), Tetralogic Pharmaceuticals (TLOG), Targeted Medical Pharma (TRGM), HST Global (HSTC), American Oriental Bioengineering (AOBI), Pivotal Therapeutics (PVTTF), Orexigen Therapeutics (OREXQ), Inspyr Therapeutics (NSPX), Epirus Biopharmaceuticals (EPRSQ), Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), Anthera Pharmaceuticals (ANTH) and Aralez Pharmaceuticals (ARLZ).
Who are Poniard Pharmaceuticals' key executives?
Poniard Pharmaceuticals' management team includes the folowing people:
- Dr. Paul G. Abrams, Exec. Officer
How do I buy shares of Poniard Pharmaceuticals?
Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Poniard Pharmaceuticals' stock price today?
One share of PARD stock can currently be purchased for approximately $0.06.
How big of a company is Poniard Pharmaceuticals?
Poniard Pharmaceuticals has a market capitalization of $70,000.00.
What is Poniard Pharmaceuticals' official website?
How can I contact Poniard Pharmaceuticals?
Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]
MarketBeat Community Rating for Poniard Pharmaceuticals (OTCMKTS PARD)
MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaceuticals and other stocks. Vote "Outperform" if you believe PARD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.
